🇺🇸 BMRN — BioMarin Pharmaceutical Inc.

Salud Compra
← Volver

Precio actual

56,03 USD

Máx. histórico

149,13

4127 días

Caída desde máximo

-62,43%

Rango 52 semanas

49,26 – 70,98

Variación hoy

-0,16%

Cierre anterior

56,12

Rango de hoy

55,00 – 56,08

Volumen hoy

2.733.184

Peor caída histórica

-90,58%

01/03/2000 → 27/08/2002

Recuperado en 1960 días

Volatilidad anualizada ⓘ

49,10%

Información
Nombre completo
BioMarin Pharmaceutical Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
3.221
PER ⓘ
150,43 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
91,04 USD (puede no estar actualizado)
Primera cotización
26/07/1999
Precio actualizado
hace 18 horas
Sobre la empresa

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
23/01/2012 35,21 35,50 34,51 34,78 -1,19% 2,81% 553.300
20/01/2012 35,54 35,75 34,91 35,20 -1,51% 2,36% 411.800
19/01/2012 35,90 36,05 35,60 35,74 -0,80% 1,25% 655.500
18/01/2012 35,79 36,10 35,40 36,03 +0,47% 1,96% 493.500
17/01/2012 35,24 36,04 34,85 35,86 +2,49% 3,38% 967.300
13/01/2012 35,28 35,40 33,93 34,99 -1,55% 4,17% 1.373.400
12/01/2012 36,20 36,38 35,36 35,54 -1,85% 2,82% 1.164.800
11/01/2012 36,90 36,91 36,09 36,21 -1,44% 2,22% 994.000
10/01/2012 37,30 37,47 36,61 36,74 -1,16% 2,31% 805.400
09/01/2012 36,80 37,82 36,04 37,17 +1,53% 4,84% 1.826.600
06/01/2012 35,54 36,66 35,47 36,61 +2,84% 3,35% 1.014.900
05/01/2012 35,13 35,94 34,76 35,60 +0,82% 3,36% 859.200
04/01/2012 34,74 35,42 34,74 35,31 +1,09% 1,96% 703.900
03/01/2012 34,48 35,60 34,23 34,93 +1,60% 3,97% 1.215.200
30/12/2011 34,08 34,76 33,96 34,38 +0,94% 2,35% 467.200
29/12/2011 33,59 34,12 33,44 34,06 +1,16% 2,02% 377.000
28/12/2011 33,51 33,81 33,25 33,67 +0,54% 1,67% 404.400
27/12/2011 33,51 33,81 33,40 33,49 -0,83% 1,22% 354.500
23/12/2011 33,80 33,91 33,47 33,77 -0,38% 1,30% 408.700
22/12/2011 33,66 33,98 33,61 33,90 +0,77% 1,10% 402.100
21/12/2011 33,31 33,66 33,04 33,64 +1,11% 1,86% 709.000
20/12/2011 32,39 33,30 32,22 33,27 +4,43% 3,33% 1.185.900
19/12/2011 31,91 32,62 31,70 31,86 +0,92% 2,88% 816.400
16/12/2011 31,24 31,67 30,98 31,57 +0,86% 2,21% 1.650.800
15/12/2011 32,30 32,58 31,29 31,30 -2,34% 3,99% 1.277.400
14/12/2011 32,16 32,52 31,52 32,05 -0,80% 3,11% 721.900
13/12/2011 33,28 33,55 32,18 32,31 -2,39% 4,12% 794.000
12/12/2011 33,39 33,48 32,86 33,10 -1,58% 1,86% 517.600
09/12/2011 33,19 33,83 33,15 33,63 +1,36% 2,05% 1.040.200
08/12/2011 33,32 33,49 32,79 33,18 +0,51% 2,10% 2.022.800